Acute Ischemic Stroke Drugs Market Forecast 2024-2033: Growth Rate, Drivers, And Trends

The Acute Ischemic Stroke Drugs Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Acute Ischemic Stroke Drugs Market:

https://www.thebusinessresearchcompany.com/report/acute-ischemic-stroke-drugs-global-market-report

According to The Business Research Company’s Acute Ischemic Stroke Drugs Global Market Report 2024, The acute ischemic stroke drugs market size has grown strongly in recent years. It will grow from $13.01 billion in 2023 to $13.66 billion in 2024 at a compound annual growth rate (CAGR) of 5.0%. The growth in the historic period can be attributed to increasing incidence of stroke, government initiatives and healthcare policies, increased awareness and education, strategic collaborations and partnerships, aging population.

The acute ischemic stroke drugs market size is expected to see strong growth in the next few years. It will grow to $16.87 billion in 2028 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to emerging therapies and drug pipeline, precision medicine and personalized therapies, global healthcare infrastructure development, increasing healthcare expenditure, telemedicine and remote patient monitoring. Major trends in the forecast period include advancements in thrombolytic therapies, neuroprotective agents development, personalized medicine and biomarker research, telemedicine and remote monitoring, collaborations and strategic partnerships.

The rise in the prevalence of chronic diseases is anticipated to propel the growth of the acute ischemic stroke drug market in the coming years. Chronic diseases, also known as non-communicable diseases, refer to conditions that endure for a year or longer and necessitate continuing medical care, restrict everyday activities, or both. The primary causes of death and disability are chronic illnesses such as heart disease, cancer, and diabetes. Acute ischemic stroke drugs are primarily used in chronic diseases to reduce the chances of clot formation and strokes and restore blood flow to the brain. For instance, in September 2022, according to the reports shared by the World Health Organization (WHO), a Switzerland-based health agency, due to chronic diseases, it is estimated 41 million people die each year, which is equivalent to 74% of all deaths globally, and 17 million individuals die before the age of 70 from chronic diseases. By 2025, an estimated 164 million Americans, or nearly 49% of the population, would be living with chronic illnesses. Therefore, the rise in the prevalence of chronic diseases is driving the growth of the acute ischemic stroke drug market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=10049&type=smp

The acute ischemic stroke drugs market covered in this report is segmented –

1) By Type: Tablet, Capsule, Other Types

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Hospitals, Diagnostic Centers, Other Applications

Strategic clinical development is a key trend gaining popularity in the acute ischemic stroke drugs market. Major companies operating in the acute ischemic stroke drugs market are focusing on clinical developments to sustain their position in the market. For instance, in May 2021, Biogen Inc., a US-based biotechnology company, purchased the investigational drug TMS-007 for acute ischemic stroke. TMS-007 has the potential to be a next-generation thrombolytic with improved benefits and risk profile. The TMS-007 Phase 2a study also demonstrated positive impacts on blood vessel reopening and patient functional recovery with no incidence of symptomatic intracranial hemorrhage.

The acute ischemic stroke drugs market report table of contents includes: